Family history and breast cancer hormone receptor status in a Spanish cohort

PLoS ONE

Volumn 7, Issue 1, 2012, Pages

  Jiang, Xuejuan ^a   Castelao, Jose Esteban ^b   Chavez Uribe, Elisabet ^c   Rodriguez, Beatriz Fernandez ^c   Muñoz, Catuxa Celeiro ^c   Redondo, Carmen M ^b   Fernandez, Maite Peña ^c   Dominguez, Alejandro Novo ^c   Pereira, Carina Doris ^c   Martínez, María Elena ^d   García Caballero, Tomás ^c   Rodriguez, Máximo Fraga ^c   Antúnez, José ^c   Carracedo, Angel ^e   Forteza Vila, Jerónimo ^c   Gago Dominguez, Manuela ^e  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY HOSPITAL COMPLEX OF VIGO   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d UNIVERSITY OF ARIZONA   (United States)

^e Galician Foundation of Genomic Medicine   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; CELL RECEPTOR;

ADULT; AGE DISTRIBUTION; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; ETHNIC GROUP; FAMILY HISTORY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; POPULATION RESEARCH; SPANISH; AGED; BREAST TUMOR; CANCER STAGING; CARCINOMA; DISEASE PREDISPOSITION; ETHNOLOGY; FAMILY HEALTH; FEMALE; METABOLISM; MIDDLE AGED; PATHOLOGY; RISK FACTOR; SPAIN; STATISTICS;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA; COHORT STUDIES; DISEASE SUSCEPTIBILITY; FAMILY HEALTH; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RISK FACTORS; SPAIN;

EID: 84855458782     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0029459     Document Type: Article

References (39)

1. Setiawan VW, Monroe KR, Wilkens LR, Kolonel LN, Pike MC, et al. (2009) Breast Cancer Risk Factors Defined by Estrogen and Progesterone Receptor Status. American Journal of Epidemiology 169: 1251-1259.
2. Colditz GA, Rosner BA, Chen WY, Holmes MD, Hankinson SE, (2004) Risk factors for breast cancer according to estrogen and progesterone receptor status. J Natl Cancer Inst 96: 218-228.
3. Hines LM, Risendal B, Slattery ML, Baumgartner KB, Giuliano AR, et al. (2008) Differences in estrogen receptor subtype according to family history of breast cancer among Hispanic, but not non-Hispanic White women. Cancer Epidemiol Biomarkers Prev 17: 2700-2706.
4. Li CI, Malone KE, Daling JR, (2003) Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med 163: 49-56.
5. Shavers VL, Harlan LC, Stevens JL, (2003) Racial/ethnic variation in clinical presentation, treatment, and survival among breast cancer patients under age 35. Cancer 97: 134-147.
6. Chu KC, Anderson WF, (2002) Rates for breast cancer characteristics by estrogen and progesterone receptor status in the major racial/ethnic groups. Breast Cancer Res Treat 74: 199-211.
7. Chu KC, Anderson WF, Fritz A, Ries LA, Brawley OW, (2001) Frequency distributions of breast cancer characteristics classified by estrogen receptor and progesterone receptor status for eight racial/ethnic groups. Cancer 92: 37-45.
8. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, et al. (2006) Race, Breast Cancer Subtypes, and Survival in the Carolina Breast Cancer Study. JAMA: The Journal of the American Medical Association 295: 2492-2502.
9. Wojcik BE, Spinks MK, Stein CR, (2003) Effects of Screening Mammography on the Comparative Survival Rates of African American, White, and Hispanic Beneficiaries of a Comprehensive Health Care System. The Breast Journal 9: 175-183.
10. Watlington AT, Byers T, Mouchawar J, Sauaia A, Ellis J, (2007) Does having insurance affect differences in clinical presentation between Hispanic and non-Hispanic white women with breast cancer? Cancer 109: 2093-2099.
11. Chavez-Uribe E, Cameselle-Teijeiro J, Vinuela JE, Castro-Pineiro C, Gude F, et al. (2007) Hypoploidy defines patients with poor prognosis in breast cancer. Oncol Rep 17: 1109-1114.
12. Ellis IO, Schnitt SJ, Sastre-Garau X, Bussolati G, Tavassoli FA, et al. (2003) Invasive breast carcinomas. In: Tavassoli FA, Devilee P, editors. World Health Organization Classification of Tumours Pathology and Genetics of Tumours of the Breast and Female Genital Organs Lyon IARC Press pp. 9-110.
13. Frierson HF Jr, Wolber RA, Berean KW, Franquemont DW, Gaffey MJ, et al. (1995) Interobserver reproducibility of the Nottingham modification of the Bloom and Richardson histologic grading scheme for infiltrating ductal carcinoma. Am J Clin Pathol 103: 195-198.
14. Chavez-Uribe EM, Vinuela JE, Cameselle-Teijeiro J, Forteza J, Punal JA, et al. (2002) DNA ploidy and cytonuclear area of peritumoral and paratumoral samples of mastectomy specimens: a useful prognostic marker? Eur J Surg 168: 37-41.
15. Galicia Xd, (2001) Galicia in the World. pp. 456-465 The exterior action of the Xunta of Galicia. Xunta de Galicia 2001.
16. Lapham SJ, (1993) 1990 Ethnic Profiles for States Washington, DC Ethnic and Hispanic Branch, Population Division, Bureau of the Census, CPH L-136.
17. Chakraborty BM, Fernandez-Esquer ME, Chakraborty R, (1999) Is being Hispanic a risk factor for non-insulin dependent diabetes mellitus (NIDDM)? Ethn Dis 9: 278-283.
18. Sans M, (2000) Admixture studies in Latin America: from the 20th to the 21st century. Hum Biol 72: 155-177.
19. Shetterly SM, Baxter J, Morgenstern NE, Grigsby J, Hamman RF, (1998) Higher instrumental activities of daily living disability in Hispanics compared with non-Hispanic whites in rural Colorado. The San Luis Valley Health and Aging Study. Am J Epidemiol 147: 1019-1027.
20. Vona-Davis L, Rose DP, (2009) The influence of socioeconomic disparities on breast cancer tumor biology and prognosis: a review. J Womens Health (Larchmt) 18: 883-893.
21. Elledge RM, Clark GM, Chamness GC, Osborne CK, (1994) Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst 86: 705-712.
22. Dunnwald L, Rossing M, Li C, (2007) Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Research 9: R6.
23. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, et al. (2004) Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 13: 1558-1568.
24. Tung N, Wang Y, Collins L, Kaplan J, Li H, et al. (2010) Estrogen receptor positive breast cancers in BRCA1 mutation carriers: clinical risk factors and pathologic features. Breast Cancer Research 12: R12.
25. Stacey SN, Manolescu A, Sulem P, Rafnar T, Gudmundsson J, et al. (2007) Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nature Genetics 39: 865-869.
26. Stacey SN, Manolescu A, Sulem P, Thorlacius S, Gudjonsson SA, et al. (2008) Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet 40: 703-706.
27. Patel TA, Colon-Otero G, Bueno Hume C, Copland JA, Perez EA, (2010) Breast Cancer in Latinas: Gene Expression, Differential Response to Treatments, and Differential Toxicities in Latinas Compared with Other Population Groups. The Oncologist 15: 466-475.
28. Baumbach L, Ahearn ME, Jorda M, Gomez C, Halsey TA, et al. (2007) Multi-ethnic Comparisons of Genome-wide Alterations in Breast Cancer Using Paraffin Embedded Samples. The American Society of Human Genetics 57th Annual Meeting. San Diego, California.
29. Symmans WF, Fiterman DJ, Anderson SK, Ayers M, Rouzier R, et al. (2005) A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding. Endocrine-Related Cancer 12: 1059-1069.
30. John EM, Miron A, Gong G, Phipps AI, Felberg A, et al. (2007) Prevalence of Pathogenic BRCA1 Mutation Carriers in 5 US Racial/Ethnic Groups. JAMA: The Journal of the American Medical Association 298: 2869-2876.
31. Llort G, Muñoz CY, Tuser MP, Guillermo IB, Lluch JRG, et al. (2002) Low frequency of recurrent BRCA1 and BRCA2 mutations in Spain. Human Mutation 19: 307-307.
32. Osorio A, Barroso A, Martinez B, Cebrian A, San Roman JM, et al. (2000) Molecular analysis of the BRCA1 and BRCA2 genes in 32 breast and/or ovarian cancer Spanish families. Br J Cancer 82: 1266-1270.
33. Diez O, Osorio A, Duran M, Martinez-Ferrandis JI, de la Hoya M, et al. (2003) Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects. Hum Mutat 22: 301-312.
34. Vega A, Torres M, Martinez JI, Ruiz-Ponte C, Barros F, et al. (2002) Analysis of BRCA1 and BRCA2 in breast and breast/ovarian cancer families shows population substructure in the Iberian peninsula. Ann Hum Genet 66: 29-36.
35. Vega A, Campos B, Bressac-De-Paillerets B, Bond PM, Janin N, et al. (2001) The R71G BRCA1 is a founder Spanish mutation and leads to aberrant splicing of the transcript. Hum Mutat 17: 520-521.
36. Weitzel JN, Lagos V, Blazer KR, Nelson R, Ricker C, et al. (2005) Prevalence of BRCA Mutations and Founder Effect in High-Risk Hispanic Families. Cancer Epidemiol Biomarkers Prev 14: 1666-1671.
37. Teixeira MR, Heim S, (2005) Multiple numerical chromosome aberrations in cancer: what are their causes and what are their consequences? Seminars in Cancer Biology 15: 3-12.
38. Theis B, Boyd N, Lockwood G, Tritchler D, (1994) Accuracy of family cancer history in breast cancer patients. Eur J Cancer Prev 3: 321-327.
39. Garcia-Closas M, Hall P, Nevanlinna H, Pooley K, Morrison J, et al. (2008) Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet 4: e1000054.